This document is a marketing communication for information purposes only and does not constitute an offer, solicitation, recommendation or investment advice. It is directed exclusively at professional investors and eligible counterparties in accordance with applicable laws and regulations and is not intended for distribution to retail investors. Applicable investor eligibility requirements and minimum investment thresholds are set out in the Fund documentation.

MTIP EverHealth Fund SA, SICAV-OPC Part II, ELTIF (the “Fund”) is a Luxembourg-domiciled European Long-Term Investment Fund investing primarily in European healthcare technology companies and related opportunities. The Fund is designed for long-term investment in illiquid assets. It has an unlimited duration and no fixed end date; it may be dissolved or wound up in accordance with the Fund documentation. The Fund is actively managed. The share classes currently offered are accumulation share classes and do not pay dividends or regular distributions. Income and capital gains are retained and reinvested within the relevant share class.

The target net return of 15–20% p.a. (in EUR) is a long-term objective derived from the Fund’s illustrative portfolio construction across direct, follow-on and indirect investments together with a liquidity sleeve, taking into account expected fund-level fees and costs. Recommended holding period: 8 years. Target returns are illustrative, not guaranteed, and actual results may differ materially. The scenarios presented are an estimate of future performance based on evidence from the past on how the value of this investment varies, and/or current market conditions and are not an exact indicator. What you will get will vary depending on how the market performs and how long you keep the investment/product.

Quarterly subscriptions and redemptions are subject to the terms of the Fund, including an initial 3-year lock-up, a 3-month notice period and applicable gates. Redemptions may be limited, deferred or suspended. The Fund’s underlying investments are long-term in nature and may be held for several years. Investors should therefore be prepared to bear the risks associated with long-term private equity investments, even where periodic redemption opportunities are offered.

The Fund may use financial derivative instruments only for the purpose of hedging risks inherent in other investments of the Fund. The use of such instruments may influence the Fund’s risk profile.

The portfolio allocations shown in this brochure are illustrative long-term target ranges. Actual allocations may vary depending on investment opportunities, portfolio development and liquidity requirements, may fall outside these ranges and may affect the Fund’s risk and return profile.

Investments are illiquid and involve risk, including the possible loss of capital. Investors should only allocate a small proportion of their overall investment portfolio to the Fund. Additional risks include valuation risk, market risk, company-specific risk, concentration risk, regulatory risk, tax risk and currency risk. Past performance is not indicative of future results. Tax treatment depends on the individual circumstances of each investor and may be subject to change in the future. Investors should seek independent tax advice.